SENSATA TECHNOLOGIES REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Swindon, United Kingdom – February 19, 2026 - Sensata Technologies (NYSE: ST) today announced financial results for its fourth quarter and full year ended December 31, 2025. "With our Q4 and Full Year 2025 results, I am pleased to report that we delivered on our objectives for the first year of our transformation journey. We expanded margins sequentially each quarter this year, dramatically improved free cash flow, strengthened ...

Financial Performance - Net income attributable to common stockholders for Q4 2025 was $0.82 per diluted share, compared to a loss of $0.56 per diluted share in Q4 2024[8]. - Core Funds from Operations (FFO) for Q4 2025 was $0.49 per diluted share, up from $0.46 per diluted share in Q4 2024[7]. - Adjusted Funds from Operations (AFFO) for Q4 2025 was $0.51 per diluted share, compared to $0.49 per diluted share in Q4 2024[7]. - Total revenues for the three months ended December 31, 2025, were $38,339,000, an increase of 7.1% from $35,742,000 in the same period of 2024[37]. - Net income attributable to the company for the three months ended December 31, 2025, was $28,335,000, compared to a net loss of $15,217,000 in the same period of 2024[39]. - Funds from operations attributable to common stockholders for the three months ended December 31, 2025, were $15,870,000, up from $15,236,000 in the same period of 2024[39]. - Adjusted EBITDA for the three months ended December 31, 2025, was $22,938,000, with an annualized figure of $91,752,000[45]. - Basic and diluted net income attributable to common stockholders per share for the three months ended December 31, 2025, was $0.82, compared to a loss of $0.56 in the same period of 2024[37]. Operational Metrics - Same-property net operating income (NOI) increased by 4.3% in Q4 2025 compared to Q4 2024, and by 4.4% for the full year[11]. - The company reported a same-property NOI of $20,466,000 for the three months ended December 31, 2025, compared to $20,246,000 in the same period of 2024[42]. - The company executed 167,000 square feet of comparable retail leases in Q4 2025, with a cash rent spread increase of 31%[11]. - The company reported a record high leased occupancy of 95.9% as of December 31, 2025, up 250 basis points from December 31, 2024[10]. Investment and Acquisitions - The company acquired Pompano Citi Centre for $65.2 million in Q4 2025, contributing to total investments of $165.9 million for the year[7]. - The Company’s investment in Alpine Income Property Trust, Inc. increased to $41,324,000 in 2025 from $39,666,000 in 2024, reflecting a growth of about 4.2%[35]. - The Company’s total real estate at cost rose to $1,060,397,000 in 2025 from $984,202,000 in 2024, an increase of approximately 7.7%[35]. Financial Position - Total liquidity as of December 31, 2025, was $167.1 million, consisting of $149.0 million of undrawn commitments and $18.1 million of cash[15]. - Total assets increased to $1,263,902,000 as of December 31, 2025, compared to $1,181,644,000 in 2024, reflecting a growth of approximately 6.9%[35]. - Long-term debt rose to $616,345,000 in 2025 from $518,993,000 in 2024, indicating an increase of about 18.8%[35]. - Cash and cash equivalents decreased to $6,467,000 in 2025 from $9,017,000 in 2024, a decline of approximately 28.3%[35]. - Total liabilities increased to $696,556,000 in 2025, up from $568,846,000 in 2024, representing a growth of around 22.5%[35]. - Retained earnings decreased to $184,886,000 in 2025 from $232,089,000 in 2024, a reduction of approximately 20.3%[35]. - The Company reported a significant increase in intangible lease liabilities, rising to $31,486,000 in 2025 from $15,124,000 in 2024, an increase of about 108%[35]. - The Company’s total stockholders' equity decreased to $567,346,000 in 2025 from $612,798,000 in 2024, a decline of approximately 7.4%[35]. Future Outlook - The 2026 outlook includes Core FFO per common share estimated between $1.98 and $2.03[18]. - The company anticipates same-property NOI growth of approximately 3.5% to 4.5% in 2026[20]. Dividends and Income - The company declared dividends of $0.38 per common share for the three months ended December 31, 2025, consistent with the same period of 2024[37]. - Interest income from commercial loans and investments increased to $3,421,000 for the three months ended December 31, 2025, from $2,950,000 in the same period of 2024[37]. - The company experienced a gain on disposition of assets of $20,079,000 for the three months ended December 31, 2025, compared to no gain in the same period of 2024[39].

Exhibit 99.1 CarGurus Announces Fourth Quarter and Full-Year 2025 Results Full-year 2025 revenue from continuing operations grew 14% YoY for the second consecutive year Full-year 2025 GAAP Net Income from continuing operations of $196.7 million, up 53% YoY; Non-GAAP Adjusted EBITDA from continuing operations of $319.0 million, up 25% YoY Repurchased approximately $350 million worth of shares in 2025, and announces new $250.0 million share repurchase program for 2026 Below are our financial highlights from c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-36773 WORKIVA INC. (Exact name of registrant as specified in its charter) ___________________________ ...

Exhibit 99.1 Accendra Health Reports Fourth Quarter 2025 Financial Results Completed Sale of Products & Healthcare Services Business On December 31, 2025 Strong Cash Flow and Debt Reduction In Quarter RICHMOND, VA – February 19, 2026 – Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company's continuing operations, which primarily represent what was previously the Patient Direct segment ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________ FORM 10-K _________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 ____________________ ...

Table of Contents Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36666 | Wayfair Inc. | | --- | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) | Delaware | | | 36-4791999 | | --- | - ...

Exhibit 99.1 ICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., February 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2025. Conference Call Fourth Quarter 2025 Results Fourth quarter 2025 revenue was $540.7 million, as compared to $629.8 million in the same period in the pri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36029 Sprouts Farmers Market, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...

Revenue Performance - Total revenue for Q4 2025 was $172.9 million, a 6.5% increase from $162.3 million in Q4 2024[4] - Revenue from material sales in Q4 2025 was $95.5 million, up from $93.3 million in Q4 2024, driven by higher unit material volume[4] - Revenue from royalty and license fees in Q4 2025 was $72.6 million, compared to $64.4 million in Q4 2024, reflecting increased unit material volume[4] - Full year 2025 total revenue was $650.6 million, slightly up from $647.7 million in 2024[7] - Full year 2025 revenue from material sales decreased to $353.0 million from $365.4 million in 2024, primarily due to changes in customer mix[7] - Full year 2025 revenue from royalty and license fees increased to $275.1 million from $266.8 million in 2024[7] Income and Profitability - Operating income for Q4 2025 was $67.2 million, compared to $52.5 million in Q4 2024, which included $8.9 million in restructuring costs[4] - Net income for Q4 2025 was $66.3 million, or $1.39 per diluted share, up from $46.0 million, or $0.96 per diluted share in Q4 2024[4] - Net income for the year ended December 31, 2025, was $242.1 million, up 9% from $222.1 million in 2024[22] - Operating income for the year ended December 31, 2025, was $248.6 million, an increase of 4.7% from $238.8 million in 2024[22] - Gross margin for Q4 2025 was $131.6 million, compared to $124.9 million in Q4 2024, reflecting a gross margin increase of 5.4%[22] Cash Flow and Dividends - Cash dividends declared per common share increased to $0.45 in Q4 2025 from $0.40 in Q4 2024, representing a 12.5% increase[22] - The company announced a cash dividend of $0.50 per share for Q1 2026, payable on March 31, 2026[11] - Net cash provided by operating activities for the year was $210.8 million, down from $253.7 million in 2024, a decrease of 16.9%[24] - The company reported a net cash used in investing activities of $45.5 million for the year, compared to $164.4 million in 2024[24] - Cash and cash equivalents at the end of 2025 were $138.4 million, up from $99.0 million at the end of 2024[24] Research and Development - Research and development expenses decreased to $38.5 million in Q4 2025 from $46.3 million in Q4 2024, a reduction of 16.0%[22] Future Outlook - The company expects 2026 revenue to be in the range of $650 million to $700 million, reflecting the dynamic OLED industry[10] Accounts Receivable - The company experienced a decrease in accounts receivable by $6.3 million in 2025, contrasting with an increase of $26.2 million in 2024[24]